A six-month legislative session kicks off in January, and policymakers plan to introduce robust health care legislation.
The Oregon Health Authority is moving to expand treatment for hepatitis C to everyone on the Oregon Health Plan who’s infected.
Three of the lawmakers who will lead the House next year as Congress focuses on skyrocketing drug costs are among the biggest recipients of campaign contributions from the pharmaceutical industry, a new KHN analysis shows.
At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.
President Donald Trump’s new pledge to crack down on “the global freeloading” in prescription drugs had a sense of déjà vu.
Oregon health experts called for greater drug pricing transparency, increased competition from foreign drug markets and better data to keep down pharmaceutical costs at an Oregon Health Forum breakfast on Tuesday.
Before the midterm elections heated up, dozens of drugmakers had already poured about $12 million into the war chests of hundreds of members of Congress.
Before the midterm elections heated up, dozens of drugmakers had already poured about $12 million into the war chests of hundreds of members of Congress.
For years, most pharmacists couldn’t give customers even a clue about an easy way to save money on prescription drugs. But the restraints are coming off.
